Inhibition of vascular smooth muscle cell proliferation and arterial intimal thickening by a novel antiproliferative naphthopyran

Todd R. Wiernicki, James S. Bean, Colin Dell, Andrew Williams, Dan Wood, Raymond F. Kauffman, Jai Pal Singh

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Smooth muscle cell proliferation plays an important role in neointimal thickening after vascular injury and may contribute to restenosis after angioplasty. Development of suitable pharmacological agents modulating smooth muscle cell proliferation is critical for further investigation of vascular hyperplasia and its prevention. In the present study, we report a novel series of compounds that inhibit smooth muscle cell proliferation and arterial intimal thickening after balloon angioplasty. LY290181 (2-amino-4- [3-pyridyl]-4H-naphtho [1, 2-b]pyran-3-carbonitrile) and LY290293 (2-amino- 4-[3-pyridyl]-4H-naphtho [1, 2-b]pyran-carbonitrile) produced a dose- dependent inhibition of DNA synthesis and proliferation of vascular smooth muscle cells in culture. Fifty percent inhibition (IC50) of cell proliferation was produced by 20 nM LY290181 or LY290293. Cell growth inhibition was not due to cell death, as demonstrated by the release of intracellular lactate dehydrogenase and by the reversibility of inhibition upon washing. Inhibition of smooth muscle cell proliferation was achieved in cells stimulated by either serum or individual growth factor such as platelet-derived growth factor, fibroblast growth factor or epidermal growth factor. In the rat model of balloon injury to carotid artery, LY290181 and LY290293 produced 61% (P < .005) and 48% (P < .005) inhibition of intimal thickening when administered p.o. at 100 and 120 mg/kg/day, respectively, over a 2-week period. Inhibition of intimal thickening (70%, P < .005) by LY290293 was also demonstrated when the compound was administered s.c. at 10 mg/kg/day. These studies demonstrate that naphthopyrans LY290181 and LY290293 are potent inhibitors of smooth muscle cell proliferation in vitro and that they produce substantial reduction in arterial intimal thickening in a balloon injury model when administered systemically.

Original languageEnglish (US)
Pages (from-to)1452-1459
Number of pages8
JournalJournal of Pharmacology and Experimental Therapeutics
Volume278
Issue number3
StatePublished - Sep 1996
Externally publishedYes

Fingerprint

LY 290293
LY 290181
Tunica Intima
Vascular Smooth Muscle
Smooth Muscle Myocytes
Cell Proliferation
Carotid Artery Injuries
Balloon Angioplasty
Fibroblast Growth Factors
Vascular System Injuries
Platelet-Derived Growth Factor
Angioplasty
L-Lactate Dehydrogenase
Epidermal Growth Factor
Inhibitory Concentration 50
Hyperplasia
Blood Vessels
Intercellular Signaling Peptides and Proteins
Cell Death
Cell Culture Techniques

ASJC Scopus subject areas

  • Pharmacology

Cite this

Wiernicki, T. R., Bean, J. S., Dell, C., Williams, A., Wood, D., Kauffman, R. F., & Singh, J. P. (1996). Inhibition of vascular smooth muscle cell proliferation and arterial intimal thickening by a novel antiproliferative naphthopyran. Journal of Pharmacology and Experimental Therapeutics, 278(3), 1452-1459.

Inhibition of vascular smooth muscle cell proliferation and arterial intimal thickening by a novel antiproliferative naphthopyran. / Wiernicki, Todd R.; Bean, James S.; Dell, Colin; Williams, Andrew; Wood, Dan; Kauffman, Raymond F.; Singh, Jai Pal.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 278, No. 3, 09.1996, p. 1452-1459.

Research output: Contribution to journalArticle

Wiernicki, TR, Bean, JS, Dell, C, Williams, A, Wood, D, Kauffman, RF & Singh, JP 1996, 'Inhibition of vascular smooth muscle cell proliferation and arterial intimal thickening by a novel antiproliferative naphthopyran', Journal of Pharmacology and Experimental Therapeutics, vol. 278, no. 3, pp. 1452-1459.
Wiernicki, Todd R. ; Bean, James S. ; Dell, Colin ; Williams, Andrew ; Wood, Dan ; Kauffman, Raymond F. ; Singh, Jai Pal. / Inhibition of vascular smooth muscle cell proliferation and arterial intimal thickening by a novel antiproliferative naphthopyran. In: Journal of Pharmacology and Experimental Therapeutics. 1996 ; Vol. 278, No. 3. pp. 1452-1459.
@article{6a9973470d974b5f8ce0e8b9f0d81ea4,
title = "Inhibition of vascular smooth muscle cell proliferation and arterial intimal thickening by a novel antiproliferative naphthopyran",
abstract = "Smooth muscle cell proliferation plays an important role in neointimal thickening after vascular injury and may contribute to restenosis after angioplasty. Development of suitable pharmacological agents modulating smooth muscle cell proliferation is critical for further investigation of vascular hyperplasia and its prevention. In the present study, we report a novel series of compounds that inhibit smooth muscle cell proliferation and arterial intimal thickening after balloon angioplasty. LY290181 (2-amino-4- [3-pyridyl]-4H-naphtho [1, 2-b]pyran-3-carbonitrile) and LY290293 (2-amino- 4-[3-pyridyl]-4H-naphtho [1, 2-b]pyran-carbonitrile) produced a dose- dependent inhibition of DNA synthesis and proliferation of vascular smooth muscle cells in culture. Fifty percent inhibition (IC50) of cell proliferation was produced by 20 nM LY290181 or LY290293. Cell growth inhibition was not due to cell death, as demonstrated by the release of intracellular lactate dehydrogenase and by the reversibility of inhibition upon washing. Inhibition of smooth muscle cell proliferation was achieved in cells stimulated by either serum or individual growth factor such as platelet-derived growth factor, fibroblast growth factor or epidermal growth factor. In the rat model of balloon injury to carotid artery, LY290181 and LY290293 produced 61{\%} (P < .005) and 48{\%} (P < .005) inhibition of intimal thickening when administered p.o. at 100 and 120 mg/kg/day, respectively, over a 2-week period. Inhibition of intimal thickening (70{\%}, P < .005) by LY290293 was also demonstrated when the compound was administered s.c. at 10 mg/kg/day. These studies demonstrate that naphthopyrans LY290181 and LY290293 are potent inhibitors of smooth muscle cell proliferation in vitro and that they produce substantial reduction in arterial intimal thickening in a balloon injury model when administered systemically.",
author = "Wiernicki, {Todd R.} and Bean, {James S.} and Colin Dell and Andrew Williams and Dan Wood and Kauffman, {Raymond F.} and Singh, {Jai Pal}",
year = "1996",
month = "9",
language = "English (US)",
volume = "278",
pages = "1452--1459",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "3",

}

TY - JOUR

T1 - Inhibition of vascular smooth muscle cell proliferation and arterial intimal thickening by a novel antiproliferative naphthopyran

AU - Wiernicki, Todd R.

AU - Bean, James S.

AU - Dell, Colin

AU - Williams, Andrew

AU - Wood, Dan

AU - Kauffman, Raymond F.

AU - Singh, Jai Pal

PY - 1996/9

Y1 - 1996/9

N2 - Smooth muscle cell proliferation plays an important role in neointimal thickening after vascular injury and may contribute to restenosis after angioplasty. Development of suitable pharmacological agents modulating smooth muscle cell proliferation is critical for further investigation of vascular hyperplasia and its prevention. In the present study, we report a novel series of compounds that inhibit smooth muscle cell proliferation and arterial intimal thickening after balloon angioplasty. LY290181 (2-amino-4- [3-pyridyl]-4H-naphtho [1, 2-b]pyran-3-carbonitrile) and LY290293 (2-amino- 4-[3-pyridyl]-4H-naphtho [1, 2-b]pyran-carbonitrile) produced a dose- dependent inhibition of DNA synthesis and proliferation of vascular smooth muscle cells in culture. Fifty percent inhibition (IC50) of cell proliferation was produced by 20 nM LY290181 or LY290293. Cell growth inhibition was not due to cell death, as demonstrated by the release of intracellular lactate dehydrogenase and by the reversibility of inhibition upon washing. Inhibition of smooth muscle cell proliferation was achieved in cells stimulated by either serum or individual growth factor such as platelet-derived growth factor, fibroblast growth factor or epidermal growth factor. In the rat model of balloon injury to carotid artery, LY290181 and LY290293 produced 61% (P < .005) and 48% (P < .005) inhibition of intimal thickening when administered p.o. at 100 and 120 mg/kg/day, respectively, over a 2-week period. Inhibition of intimal thickening (70%, P < .005) by LY290293 was also demonstrated when the compound was administered s.c. at 10 mg/kg/day. These studies demonstrate that naphthopyrans LY290181 and LY290293 are potent inhibitors of smooth muscle cell proliferation in vitro and that they produce substantial reduction in arterial intimal thickening in a balloon injury model when administered systemically.

AB - Smooth muscle cell proliferation plays an important role in neointimal thickening after vascular injury and may contribute to restenosis after angioplasty. Development of suitable pharmacological agents modulating smooth muscle cell proliferation is critical for further investigation of vascular hyperplasia and its prevention. In the present study, we report a novel series of compounds that inhibit smooth muscle cell proliferation and arterial intimal thickening after balloon angioplasty. LY290181 (2-amino-4- [3-pyridyl]-4H-naphtho [1, 2-b]pyran-3-carbonitrile) and LY290293 (2-amino- 4-[3-pyridyl]-4H-naphtho [1, 2-b]pyran-carbonitrile) produced a dose- dependent inhibition of DNA synthesis and proliferation of vascular smooth muscle cells in culture. Fifty percent inhibition (IC50) of cell proliferation was produced by 20 nM LY290181 or LY290293. Cell growth inhibition was not due to cell death, as demonstrated by the release of intracellular lactate dehydrogenase and by the reversibility of inhibition upon washing. Inhibition of smooth muscle cell proliferation was achieved in cells stimulated by either serum or individual growth factor such as platelet-derived growth factor, fibroblast growth factor or epidermal growth factor. In the rat model of balloon injury to carotid artery, LY290181 and LY290293 produced 61% (P < .005) and 48% (P < .005) inhibition of intimal thickening when administered p.o. at 100 and 120 mg/kg/day, respectively, over a 2-week period. Inhibition of intimal thickening (70%, P < .005) by LY290293 was also demonstrated when the compound was administered s.c. at 10 mg/kg/day. These studies demonstrate that naphthopyrans LY290181 and LY290293 are potent inhibitors of smooth muscle cell proliferation in vitro and that they produce substantial reduction in arterial intimal thickening in a balloon injury model when administered systemically.

UR - http://www.scopus.com/inward/record.url?scp=0030436858&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030436858&partnerID=8YFLogxK

M3 - Article

VL - 278

SP - 1452

EP - 1459

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 3

ER -